Literature DB >> 2547724

Modulation of human peripheral blood eosinophil function by tumor necrosis factor-alpha.

E A Whitcomb1, J H Wesolek, S H Pincus.   

Abstract

Eosinophils are important effectors in helminthic parasitic infection. Tumor necrosis factor (TNF-alpha) has been implicated as a mediator in the host response to parasitic infection and enhances eosinophil-mediated helminthotoxicity. We have examined the direct effects of recombinant human (rh) TNF on eosinophil functions of degranulation and oxidative metabolism. This report describes the minimal effects of rhTNF-alpha on eosinophil superoxide anion generation and enzyme secretion, which do not satisfactorily explain the observed increases in helminthotoxicity. In contrast to other cell types, eosinophils are unique in their differential responses to interleukin-1 beta and TNF.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2547724     DOI: 10.1159/000234955

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  4 in total

Review 1.  Evaluation of TNF as antiviral, antibacterial and antiparasitic agent.

Authors:  G A Rook; J Taverne; J H Playfair
Journal:  Biotherapy       Date:  1991

2.  The direct effect of interferon-gamma on human eosinophilic leukemia cell lines: the induction of interleukin-5 mRNA and the presence of an interferon-gamma receptor.

Authors:  T Ishizuka; K Morita; T Hisada; T Ishizuka; S Ando; M Adachi; K Dobashi; M Mori
Journal:  Inflammation       Date:  1996-04       Impact factor: 4.092

3.  Activation of p38 mitogen-activated protein kinase and nuclear factor-kappaB in tumour necrosis factor-induced eotaxin release of human eosinophils.

Authors:  C K Wong; J P Zhang; W K Ip; C W K Lam
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

4.  Intracellular application of guanosine-5'-O-(3-thiotriphosphate) induces exocytotic granule fusion in guinea pig eosinophils.

Authors:  O Nüsse; M Lindau; O Cromwell; A B Kay; B D Gomperts
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.